Skip to main content
. Author manuscript; available in PMC: 2018 Aug 9.
Published in final edited form as: Chem Rev. 2017 Jun 27;117(15):10043–10120. doi: 10.1021/acs.chemrev.7b00042

Figure 22.

Figure 22

Mito-CP-Induced Mitigation of the Inflammatory Response in Kidneys of Mice Treated with Cisplatin. Mito-CP attenuates cisplatin-induced inflammation. Cisplatin significantly increased mRNA expression of proinflammatory chemokines (A) MCP-1, (B) MIP1α and MIP2, (C and D) myeloperoxidase staining and activity, and (E and F) adhesion molecule ICAM-1 and proinflammatory cytokine TNF-α mRNA expression in the kidneys 72 h after its administration to mice, indicating enhanced inflammatory response. These changes could be largely prevented by treatment with Mito-CP. Results are means±SEM of 6–16/group. *P < 0.05 vs. vehicle; #P < 0.05 vs. cisplatin. (Adapted with permission from Ref.490. Reprinted from Free Radical Biology and Medicine, 52/2, Mukhopadhyay P, Horváth B, Zsengellér Z, Zielonka J, Tanchian G, Holovac E, Kechrid M, Patel V, Stillman IE, Parikh SM, Joseph J, Kalyanaraman B, Pacher P, Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy, 497–506, Copyright 2012, with permission from Elsevier.)